CJM Wealth Advisers Ltd. Invests $649,000 in Eli Lilly and Company (NYSE:LLY)

CJM Wealth Advisers Ltd. purchased a new stake in Eli Lilly and Company (NYSE:LLY) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 732 shares of the company’s stock, valued at approximately $649,000.

A number of other hedge funds have also bought and sold shares of the business. J. W. Coons Advisors LLC lifted its stake in shares of Eli Lilly and Company by 4.0% in the 4th quarter. J. W. Coons Advisors LLC now owns 2,324 shares of the company’s stock valued at $1,355,000 after acquiring an additional 90 shares during the last quarter. Exencial Wealth Advisors LLC raised its position in Eli Lilly and Company by 4.0% in the fourth quarter. Exencial Wealth Advisors LLC now owns 7,454 shares of the company’s stock valued at $4,345,000 after purchasing an additional 286 shares during the last quarter. Morningstar Investment Services LLC boosted its stake in shares of Eli Lilly and Company by 81.9% during the fourth quarter. Morningstar Investment Services LLC now owns 3,167 shares of the company’s stock valued at $1,840,000 after purchasing an additional 1,426 shares in the last quarter. Angeles Investment Advisors LLC grew its holdings in shares of Eli Lilly and Company by 13.0% during the fourth quarter. Angeles Investment Advisors LLC now owns 461 shares of the company’s stock worth $269,000 after purchasing an additional 53 shares during the last quarter. Finally, Frank Rimerman Advisors LLC acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $37,000. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LLY has been the subject of several recent research reports. Guggenheim upped their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Berenberg Bank increased their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research note on Wednesday, August 14th. Jefferies Financial Group upped their target price on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Finally, Truist Financial restated a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a research report on Tuesday, June 25th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $977.35.

Insiders Place Their Bets

In related news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the transaction, the insider now directly owns 96,943,810 shares in the company, valued at $91,109,731,514.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 0.7 %

LLY stock opened at $885.15 on Friday. The stock has a 50-day simple moving average of $898.50 and a two-hundred day simple moving average of $846.49. Eli Lilly and Company has a twelve month low of $523.63 and a twelve month high of $972.53. The firm has a market capitalization of $841.25 billion, a PE ratio of 130.36, a PEG ratio of 2.78 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 EPS for the quarter, beating the consensus estimate of $2.64 by $1.28. The company had revenue of $11.30 billion during the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. On average, equities analysts predict that Eli Lilly and Company will post 16.49 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.